Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
David E GerberRonan J Kelly

Abstract

KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analysis of KRAS mutant cancers in an earlier phase 2 study of erlotinib plus the oral MET inhibitor tivantinib, combination therapy was associated with substantial clinical benefit compared to erlotinib alone (progression-free survival [PFS] HR 0.18; P < 0.01). The current study was conducted to evaluate this combination further in KRAS mutant non-small cell lung cancer (NSCLC). Previously treated patients with advanced KRAS mutant NSCLC were randomized to receive either oral tivantinib (360 mg twice daily) plus erlotinib (150 mg daily) (ET) or single-agent chemotherapy (investigator's choice of pemetrexed, docetaxel, or gemcitabine) (C). The primary endpoint was PFS. At progression, crossover from C to ET was permitted. Ninety-six patients were randomly assigned to ET (n = 51) or to C (n = 45). Median PFS was 1.7 months (mos) for ET and 4.3 mos for C (HR 1.19; 95% CI, 0.71-1.97; P = 0.50). There was no difference in overall survival (HR 1.20; 95% CI...Continue Reading

References

Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·H TakayamaG Merlino
Dec 20, 2003·Nature Reviews. Molecular Cell Biology·Carmen BirchmeierGeorge F Vande Woude
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erminia MassarelliIgnacio I Wistuba
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chang-Qi ZhuUNKNOWN National Cancer Institute of Canada Clinical Trials Group Study BR.21
Oct 7, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CappuzzoM Varella-Garcia
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico CappuzzoMarileila Varella-Garcia
Jul 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katharina SchmidMartin Filipits
Feb 5, 2010·Cancer Cell·Alexa B TurkePasi A Jänne
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy A YapJohann S de Bono
Jul 8, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Aya TanakaShinya Kimura
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistJoan H Schiller
Oct 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lee S RosenRobert Dreicer
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Jun 1, 2012·Journal of Environmental and Public Health·Heather RyanJoe Gfroerer
Jul 11, 2012·Chinese Journal of Cancer·Peter M K Westcott, Minh D To
Nov 6, 2012·Clinical Lung Cancer·Niki KarachaliouRafael Rosell
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelAmy C Peterson
Nov 22, 2013·Angewandte Chemie·Sang Min LimNathanael S Gray
May 23, 2014·JAMA : the Journal of the American Medical Association·Mark G KrisPaul A Bunn
Feb 14, 2015·Clinical Pharmacology and Therapeutics·D E GerberR Govindan
Apr 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C LimN B Leighl
Jan 15, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Charles LimNatasha B Leighl
Jan 23, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Susan E JorgeDaniel B Costa
Mar 30, 2016·The Oncologist·Rebecca S HeistA John Iafrate
Jun 4, 2017·Clinical Lung Cancer·Sandra GarciaDavid E Gerber

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Giorgio V ScagliottiWallace Akerley
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Thomas J LynchFrances A Shepherd
© 2022 Meta ULC. All rights reserved